Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 5/20 | 0.59 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.46 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.46 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.46 |
| ▸ | GJB2 | P29033 | 1/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.41 |
| ▸ | TNF | P01375 | 1/20 | 0.40 |
| ▸ | CETP | P11597 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8443464 | 1.00 | GBA1 (0.59) | GBA1SLC2A1MAPK1LGALS8LGALS3 | |
| SCHEMBL736485 | 1.00 | GBA1 (0.59) | GBA1SLC2A1MAPK1LGALS8LGALS3 | |
| SCHEMBL5029670 | 1.00 | GBA1 (0.59) | GBA1SLC2A1MAPK1LGALS8LGALS3 | |
| SCHEMBL1134708 | 1.00 | GBA1 (0.59) | GBA1SLC2A1MAPK1LGALS8LGALS3 | |
| SCHEMBL9291634 | 1.00 | GBA1 (0.59) | GBA1SLC2A1MAPK1LGALS8LGALS3 | |
| SCHEMBL23646744 | 1.00 | GBA1 (0.59) | GBA1SLC2A1MAPK1LGALS8LGALS3 | |
| SCHEMBL4391706 | 1.00 | GBA1 (0.59) | GBA1SLC2A1MAPK1LGALS8LGALS3 | |
| SCHEMBL8940690 | 1.00 | GBA1 (0.59) | GBA1SLC2A1MAPK1LGALS8LGALS3 | |
| SCHEMBL258033 | 1.00 | GBA1 (0.59) | GBA1SLC2A1MAPK1LGALS8LGALS3 | |
| SCHEMBL4912663 | 1.00 | GBA1 (0.59) | GBA1SLC2A1MAPK1LGALS8LGALS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 178 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3661475-A1 | WNT COMPOSITIONS AND METHODS OF PROCESS FROM SERUM-FREE CULTURING CONDITIONS | Ankasa Regenerative Therapeutics, Inc. (US) | 2020-06-10 | — | — | EP | claimed |
| WO-2019028186-A1 | WNT COMPOSITIONS AND METHODS OF PROCESS FROM SERUM-FREE CULTURING CONDITIONS | ANKASA REGENERATIVE THERAPEUTICS, INC. (US) | 2019-02-07 | — | — | WO | claimed |
| EP-2031968-B1 | STRUCTURALLY MODIFIED ACELLULAR TISSUE ENGINEERING SCAFFOLDS AND METHODS OF PRODUCTION | UNIV WAKE FOREST HEALTH SCIENCES (US) | 2017-11-22 | — | — | EP | claimed |
| US-20100151451-A1 | Method for Identifying the Genotype in Position 171 of the Ovine Prion Protein as well as Kits for Implementing said Method | BIO-RAD PASTEUR (FR) | 2010-06-17 | — | — | US | claimed |
| EP-1244396-B2 | METHODS FOR ORGAN DECELLULARIZATION | CHILDRENS MEDICAL CENTER (US) | 2009-02-11 | — | — | EP | claimed |
| EP-1952153-A2 | METHOD FOR IDENTIFYING THE GENOTYPE IN POSITION 171 OF THE OVINE PRION PROTEIN AS WELL AS KITS FOR IMPLEMENTING SAID METHOD | Bio-Rad Pasteur (FR) | 2008-08-06 | — | — | EP | claimed |
| US-7236236-B2 | Methods for detecting malaria parasites and reagent kits therefor | SYSMEX CORPORATION (JP) | 2007-06-26 | — | — | US | claimed |
| WO-2007060373-A2 | METHOD FOR IDENTIFYING THE GENOTYPE IN POSITION 171 OF THE SHEEP PRION PROTEIN AS WELL AS KITS FOR IMPLEMENTING SAID METHOD | BIO-RAD PASTEUR (FR) | 2007-05-31 | — | — | WO | claimed |
| US-7223410-B1 | Inactivated respiratory syncytial viral vaccines | SANOFI PASTEUR LIMITED (CA) | 2007-05-29 | — | — | US | claimed |
| US-7083795-B1 | Inactivated respiratory syncytial viral vaccines | SANOFI PASTEUR LIMITED (CA) | 2006-08-01 | — | — | US | claimed |
| US-20060068390-A1 | Dna amplification and sequencing in collapsible emulsions | NUCLEICS PTY LTD. (AU) | 2006-03-30 | — | — | US | claimed |
| EP-1244396-B1 | METHODS FOR ORGAN DECELLULARIZATION | CHILDRENS MEDICAL CENTER (US) | 2005-11-09 | — | — | EP | claimed |
| US-20030134420-A1 | Methods and compositions for gene delivery | IMMUNE RESPONSE CORPORATION, THE | 2003-07-17 | — | — | US | claimed |
| US-6395469-B1 | DETECTING PREFERENTIAL ANTIBODIES IN SAMPLE; OBTAIN SAMPLE, INCUBATE WITH DEACTIVATED VIRAL ANTIGENS, DETECT IMMUNE COMPLEX FORMATION | AVENTIS PASTEUR LIMITED (CA) | 2002-05-28 | — | — | US | claimed |
| WO-2001060415-A1 | METHODS AND COMPOSITIONS FOR GENE DELIVERY | THE IMMUNE RESPONSE CORPORATION (US) | 2001-08-23 | — | — | WO | claimed |
| EP-0714306-B1 | INACTIVATED RESPIRATORY SYNCYTIAL VIRAL VACCINES | CONNAUGHT LAB (CA) | 1998-03-25 | — | — | EP | claimed |
| EP-0714306-A1 | INACTIVATED RESPIRATORY SYNCYTIAL VIRAL VACCINES | CONNAUGHT LABORATORIES LIMITED (CA) | 1996-06-05 | — | — | EP | claimed |
| WO-1995004545-A1 | INACTIVATED RESPIRATORY SYNCYTIAL VIRAL VACCINES | CONNAUGHT LABORATORIES LIMITED (CA) | 1995-02-16 | — | — | WO | claimed |
| US-5286625-A | Pretreatment with nitric acid and surfactant | SEIKAGAKU CORPORATION (JP) | 1994-02-15 | — | — | US | claimed |
| EP-0005864-B1 | ANTIGENIC COMPOSITION USEFUL AS A VACCINE OR VACCINE INTERMEDIATE, AND PROCESS FOR PREPARING SAME | New York Blood Center, Inc. (US) | 1981-10-21 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030134420-A1 | Methods and compositions for gene delivery | POLRMT, NUP205, POLM | GBA1 408/4885SLC2A1 533/4885MAPK1 4702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.